Research Topics
Species | Rakesh JainSummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?Sergey V Kozin
Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, COX 734, Boston, MA 02114, USA
J Natl Cancer Inst 104:899-905. 2012....
Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategiesVikash P Chauhan
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Annu Rev Chem Biomol Eng 2:281-98. 2011..We then highlight strategies for overcoming these barriers by modulating either drug properties or the tumor microenvironment itself to enhance the delivery and effectiveness of drugs in tumors...- Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancerPhilip J Saylor
Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
Oncologist 17:212-9. 2012..We measured inflammatory and angiogenic biomarkers in ADT-treated and control groups of men with prostate cancer... 
Angiogenesis in brain tumoursRakesh K Jain
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, Massachusetts 02114, USA
Nat Rev Neurosci 8:610-22. 2007..This creates a window of opportunity for optimally combining chemotherapeutics and radiation...- What brings pericytes to tumor vessels?Rakesh K Jain
Edwin L Steele Laboratory, Department of Radiation Oncology, Boston, Massachusetts 02114, USA
J Clin Invest 112:1134-6. 2003..A new study (see the related article beginning on page 1142) reveals that it is not just the presence of PDGFB, but how it is presented to pericytes, that determines the quality of the endothelium-pericyte interaction... - Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilizationRakesh K Jain
Harvard Medical School and Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Nat Clin Pract Cardiovasc Med 4:491-502. 2007..The development of this novel approach to prevent plaque progression might add to the armamentarium of preventive measures for acute myocardial infarction, stroke and sudden cardiac death... - Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical modelRakesh K Jain
E L Steele Lab for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 67:2729-35. 2007..Finally, decreased fluid convection into the peritumor tissue would decrease peritumor edema associated with brain tumors and ascites accumulation in the peritoneal or pleural cavity, a major complication with a number of malignancies... - Normalization of tumor vasculature: an emerging concept in antiangiogenic therapyRakesh K Jain
E L Steele Lab for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, COX 7, 100 Blossom Street, Boston, MA 02114, USA
Science 307:58-62. 2005.... - Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancerRakesh K Jain
Edwin L Steele Laboratory for Tumour Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, COX 7, Boston, Massachusetts 02114, USA
Nat Rev Cancer 8:309-16. 2008.... - Lessons from phase III clinical trials on anti-VEGF therapy for cancerRakesh K Jain
Department of Radiation Oncology, Harvard Medical School, and Massachusetts General Hospital, Boston, MA 02114, USA
Nat Clin Pract Oncol 3:24-40. 2006..We summarize three of the many potential mechanisms of action of anti-VEGF agents, and also discuss progress relating to the identification of potential biomarkers for anti-VEGF-agent efficacy in humans... - Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse modelRakesh K Jain
Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
PLoS Med 5:e24. 2008 - Antiangiogenic therapy for cancer: current and emerging conceptsRakesh K Jain
E L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Oncology (Williston Park) 19:7-16. 2005..This paper reviews current and emerging concepts of the mechanism of action of antiangiogenic therapies and discusses the implications of these mechanisms for their optimal clinical use... - alphaPlGF: a new kid on the antiangiogenesis blockRakesh K Jain
Steele Lab of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Cell 131:443-5. 2007..In this issue, Fischer et al. (2007) offer compelling evidence that a monoclonal antibody against placental growth factor (PlGF), a member of the VEGF family, has such potential in mice... - Molecular regulation of vessel maturationRakesh K Jain
E L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, Massachusetts 02114, USA
Nat Med 9:685-93. 2003..Normalization of the abnormal vasculature can facilitate drug delivery to tumors and formation of a mature vasculature can help realize the promise of therapeutic angiogenesis and tissue engineering... - Delivering nanomedicine to solid tumorsRakesh K Jain
Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
Nat Rev Clin Oncol 7:653-64. 2010..Finally, we discuss design considerations for optimizing the delivery of nanoparticles to tumors... - Dissecting tumour pathophysiology using intravital microscopyRakesh K Jain
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
Nat Rev Cancer 2:266-76. 2002..Intravital microscopy has provided unprecedented molecular, cellular, anatomical and functional insights into these barriers and has revealed new approaches to improved detection and treatment... - Intratumoral lymphatic vessels: a case of mistaken identity or malfunction?Rakesh K Jain
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, COX 7, Boston, MA 02114, USA
J Natl Cancer Inst 94:417-21. 2002 - Biomarkers of response and resistance to antiangiogenic therapyRakesh K Jain
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
Nat Rev Clin Oncol 6:327-38. 2009.... - Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factorR K Jain
Edwin L Steele Laboratory, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114, USA
Proc Natl Acad Sci U S A 95:10820-5. 1998..Because human tumors often relapse following hormone-ablation therapy, our data suggest that these patients may benefit from combined anti-VEGF therapy... - Transport of molecules, particles, and cells in solid tumorsR K Jain
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Annu Rev Biomed Eng 1:241-63. 1999.... - Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and functionR K Jain
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Control Release 74:7-25. 2001.... - Delivery of molecular and cellular medicine to solid tumorsR K Jain
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Adv Drug Deliv Rev 46:149-68. 2001.... - Delivery of molecular and cellular medicine to solid tumorsR K Jain
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
J Control Release 53:49-67. 1998.... - Development. Lymphatics make the breakRakesh K Jain
Edwin L. Steele Laboratory of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Science 299:209-10. 2003 - Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinasesFrank Winkler
E.L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
Cancer Cell 6:553-63. 2004..During the normalization window, but not before or after it, VEGFR2 blockade increases pericyte coverage of brain tumor vessels via upregulation of Ang1 and degrades their pathologically thick basement membrane via MMP activation... - Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumorsWayne L Monsky
Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Clin Cancer Res 8:1008-13. 2002..Collectively, host microenvironment is an important determinant of tumor gene expression and microvascular functions, and, thus, orthotopic breast tumor models should be useful for obtaining clinically relevant information... - PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatmentEmmanuelle di Tomaso
E L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
PLoS ONE 4:e5123. 2009..Here we tested the hypothesis that Platelet Derived Growth Factor-C (PDGF-C), an isoform of the PDGF family, affects GBM progression independent of VEGF pathway and hinders anti-VEGF therapy... - Lymphatic metastasis in the absence of functional intratumor lymphaticsTimothy P Padera
E. L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
Science 296:1883-6. 2002..These findings suggest that the functional lymphatics in the tumor margin alone are sufficient for lymphatic metastasis and should be targeted therapeutically... - AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsTracy T Batchelor
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Cancer Cell 11:83-95. 2007..Our study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor... - Angiogenesis as a therapeutic target in malignant gliomasAndrew S Chi
Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
Oncologist 14:621-36. 2009..Although challenges remain with this approach, ongoing studies may improve upon the promising initial benefits already observed in GBM patients... - Tumor angiogenesis and accessibility: role of vascular endothelial growth factorRakesh K Jain
Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, 100 Blossom Street-Box 7, Boston, MA 02114, USA
Semin Oncol 29:3-9. 2002.... - Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancerLei Xu
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 69:7905-10. 2009..These data show that VEGF blockade up-regulates inflammatory pathways and NRP1, which should be evaluated as potential targets for improving anti-VEGF therapy... - Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasisJohanna Lahdenranta
Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 69:2801-8. 2009..Our findings explain the correlation between NOS and lymphatic metastasis seen in a number of human tumors and open the door for potential therapies exploiting NO signaling to treat diseases of the lymphatic system... - Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumorsHon Kit Wong
Department of Radiation Oncology, Steele Laboratory, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
Cancer Res 70:3483-93. 2010..This study shows that anti-VEGF therapy normalizes the vasculature of schwannoma xenografts in nude mice and successfully controls the tumor growth, probably by reestablishing a natural balance between VEGF and semaphorin 3 signaling... - Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumorsSergey V Kozin
Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 67:5076-82. 2007..Our findings suggest that antiangiogenic agents could be effective in the treatment of patients with relapses after radiotherapy... - Green fluorescent protein (GFP)-expressing tumor model derived from a spontaneous osteosarcoma in a vascular endothelial growth factor (VEGF)-GFP transgenic mousePeigen Huang
Department of Radiation Oncology, Edwin L. Steele Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Comp Med 55:236-43. 2005..This in vitro and in vivo transplantable and metastatic osteosarcoma (Os-P0107) is an attractive model for further study of tumor pathophysiology and treatment efficiency affecting VEGF expression... - Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiationSergey V Kozin
Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 70:5679-85. 2010..Our results suggest that an increase in intratumoral SDF-1alpha triggered by LI recruits myelomonocytes/macrophages which promotes tumor regrowth... - Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor
Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
J Clin Oncol 28:2817-23. 2010..Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma... - Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markersEmmanuelle di Tomaso
Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Cancer Res 65:5740-9. 2005..More than 80% of the defects lacked immunoreactivity for multiple basement membrane proteins... - Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II studyChristopher G Willett
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 27:3020-6. 2009..To assess the safety and efficacy of neoadjuvant bevacizumab with standard chemoradiotherapy in locally advanced rectal cancer and explore biomarkers for response... - Differential gene expression in metastasizing cells shed from kidney tumorsMaximilian Bockhorn
Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
Cancer Res 64:2469-73. 2004..Furthermore, resistance to apoptosis may enhance metastasis in the higher metastatic tumor... - Taming vessels to treat cancerRakesh K Jain
Radiation Oncology Department, Massachusetts General Hospital and Harvard Medical School, USA
Sci Am 298:56-63. 2008 - Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in miceWalid S Kamoun
Edwin L Steele Laboratory, Department of Radiation Oncology, Stephen E and Catherine Pappas Center for Neuro Oncology, and AA Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Clin Oncol 27:2542-52. 2009..Our goal was to determine whether alleviation of edema by anti-VEGF agents alone could increase survival in mice... - Paradoxical effects of PDGF-BB overexpression in endothelial cells on engineered blood vessels in vivoPatrick Au
Department of RadiationOncology, Edwin L Steele Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
Am J Pathol 175:294-302. 2009..These results suggest a potential negative interaction between angiogenic growth factors and vascular cells; their use in combination should be carefully tested in vivo for such opposing effects... - Diffusion and convection in collagen gels: implications for transport in the tumor interstitiumSaroja Ramanujan
E. L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Biophys J 83:1650-60. 2002..These findings have significant implications for drug delivery in tumors and for tissue engineering applications... - Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumorsDan G Duda
Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, COX 734, 100 Blossom St, Boston, MA 02114, USA
Blood 107:2774-6. 2006..We demonstrate that BMD-ECs incorporate in perfused tumor vessels, and that this contribution varies with organ site and mouse strain... - Quantum dots spectrally distinguish multiple species within the tumor milieu in vivoMark Stroh
E.L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
Nat Med 11:678-82. 2005..These examples show the versatility of quantum dots for studying tumor pathophysiology and creating avenues for treatment... - Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumorsRicky T Tong
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 64:3731-6. 2004..Thus, vascular normalization may contribute to the improved survival rates in tumor-bearing animals and in colorectal carcinoma patients treated with an anti-VEGF antibody in combination with cytotoxic therapies... - NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vesselsSatoshi Kashiwagi
Edwin L. Steele Laboratory, Department of Radiation Oncology, and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
J Clin Invest 115:1816-27. 2005..These data indicate that endothelial cell-derived NO induces mural cell recruitment as well as subsequent morphogenesis and stabilization of angiogenic vessels... - Tumour biology: herceptin acts as an anti-angiogenic cocktailYotaro Izumi
Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Nature 416:279-80. 2002..As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments... - Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGFLei Xu
Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114, USA
J Biol Chem 277:11368-74. 2002..These results show that acidic pH activates Ras and the ERK1/2 MAPK pathway to enhance VEGF transcription via AP-1, leading to increased VEGF production... - Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isograftsYotaro Izumi
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 63:747-51. 2003..Although passaged tumors behave differently, it is encouraging that the tumor growth rates under DC101 treatment are comparable among different passage generations... - Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanibTimothy P Padera
Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
Mol Cancer Ther 7:2272-9. 2008..Collectively, these data indicate that the response of lymphatic vessels to a TKI can determine the incidence of lymphatic metastasis, independent of the effect of the TKI on blood vessels... - Perivascular nitric oxide gradients normalize tumor vasculatureSatoshi Kashiwagi
Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, Massachusetts 02114, USA
Nat Med 14:255-7. 2008..Creation of perivascular NO gradients may be an effective strategy for normalizing abnormal vasculature... - Conventional and high-speed intravital multiphoton laser scanning microscopy of microvasculature, lymphatics, and leukocyte-endothelial interactionsTimothy P Padera
Massachusetts General Hospital, Boston, MA 02114, USA
Mol Imaging 1:9-15. 2002..Future applications will include the use of MPLSM in combination with fluorescent reporters to give novel insight into the regulation and function of genes... - In vivo imaging of extracellular matrix remodeling by tumor-associated fibroblastsJean Y Perentes
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, Massachusetts 02114, USA
Nat Methods 6:143-5. 2009..We show that the matrix-modifying hormone relaxin increased tumor-associated fibroblast (TAF) interaction with collagen fibers by stimulating beta1-integrin activity, which is necessary for fiber remodeling by matrix metalloproteinases... - Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)Patrick Y Wen
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, SW430D, 44 Binney St, Boston, MA 02115, USA
Neuro Oncol 11:853-60. 2009..Single-agent imatinib was well tolerated but had no significant activity in recurrent meningiomas. Trough plasma concentrations of imatinib exceeded those associated with imatinib activity in chronic myelogenous leukemia... - Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranibElizabeth R Gerstner
Departments of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
Neuro Oncol 12:466-72. 2010..ADC maps can be used to suggest regions of infiltrative tumor cells with anti-VEGF therapy and should be validated in future studies... - Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesisDai Fukumura
Edwin L. Steele Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Mass 02114, USA
Circ Res 93:e88-97. 2003..The full text of this article is available online at http://www.circresaha.org... - A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapyBrian R Stoll
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Blood 102:2555-61. 2003..The model offers new insight into tumor angiogenesis with implications for the rational design of antiangiogenic therapy... - Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumorsGeorge Alexandrakis
Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Nat Med 10:203-7. 2004..The ratio of these two components depends on molecular size and can be altered in vivo with hyaluronidase and collagenase. These studies indicate that TPFCM is a promising tool to dissect the barriers to drug delivery in tumors... - Targeted therapy in rectal cancerChristopher G Willett
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27705, USA
Oncology (Williston Park) 21:1055-65; discussion 1065, 1070, 1075 passim. 2007..This review will address completed and ongoing trials that have established and continue to clarify the effects of these agents in rectal cancer... - Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implicationsTohru Hoshida
Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Cancer Res 66:8065-75. 2006.... - Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatmentThomas J Spencer
Massachusetts General Hospital Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
J Child Adolesc Psychopharmacol 17:689-700. 2007..To examine the effects on growth of long-term pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), we present findings from an ongoing 5-year study of the efficacy and safety of treatment with atomoxetine... - Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinomaLei Xu
Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, COX 7, Boston, MA 02114, USA
Mol Cancer Res 5:873-80. 2007.... - Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical modelsDai Fukumura
Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Microcirculation 17:206-25. 2010..Administration of cytotoxic therapy during periods of vascular normalization has the potential to enhance treatment efficacy... - VEGF inhibitors in the treatment of cerebral edema in patients with brain cancerElizabeth R Gerstner
Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Nat Rev Clin Oncol 6:229-36. 2009..Anti-VEGF agents might also be useful in other cancer-related conditions that increase vascular permeability, such as malignant pleural effusions or ascites... - Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalizationDai Fukumura
Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street Cox 7, Boston, MA 02114, USA
Microvasc Res 74:72-84. 2007..Combination of cytotoxic therapy and anti-angiogenic treatment during the vascular normalization exhibits synergistic effect... - The role of nitric oxide in tumour progressionDai Fukumura
Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Nat Rev Cancer 6:521-34. 2006..We also discuss potential strategies for cancer treatment that modulate NO production and/or its downstream signalling pathways... - Imaging angiogenesis and the microenvironmentDai Fukumura
Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
APMIS 116:695-715. 2008..Administration of cytotoxic therapy during the vascular normalization would enhance its efficacy... - Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N micePeigen Huang
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Comp Med 58:253-63. 2008..Establishment of these novel tumor lines will benefit both in vivo and in vitro studies on the pathophysiology of cancer in this relatively new but widely used mouse strain... - VEGFR3: a new target for antiangiogenesis therapy?Timothy P Padera
Edwin L Steele Laboratory of Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Dev Cell 15:178-9. 2008..Tammela et al. in Nature show that VEGFR-3, via Notch regulation, is present on endothelial tip cells and is critical to sprouting angiogenesis... - Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patientsChristopher G Willett
J Clin Oncol 23:8136-9. 2005 - VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospectsDan G Duda
Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, COX 734, Boston, MA 02114, USA
Trends Mol Med 13:223-30. 2007.... - Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapyDan G Duda
Steele Laboratory for Tumor Biology, Department of Radiation Oncology and Center for Regenerative Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Clin Oncol 24:1449-53. 2006..CD146 is considered a panendothelial-specific marker, but its utility as a CEC marker in cancer patients remains unclear... - Irradiation reduces interstitial fluid transport and increases the collagen content in tumorsCynthia A Znati
Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA
Clin Cancer Res 9:5508-13. 2003..CONCLUSIONS: After irradiation, the decrease in K and increase in collagen type I levels could significantly hinder the convective movement and diffusion of large therapeutic agents in tumors... - Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse modelsLei Xu
Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 66:3971-7. 2006..Our study shows that PlGF overexpression decreases VEGF homodimer formation and inhibits tumor progression... - Small blood vessel engineeringPatrick Au
Department of Radiation Oncology, Edwin L Steele Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, USA
Methods Mol Med 140:183-95. 2007..The engineered vessels are stable and functional, and they persist for more than 1 year in vivo. This approach may potentially lead to the creation of a well-vascularized-engineered tissue... - Pathology: cancer cells compress intratumour vesselsTimothy P Padera
Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Nature 427:695. 2004..By reducing this compressive mechanical force and opening vessels, cytotoxic cancer treatments have the potential to increase blood perfusion, thereby improving drug delivery... - Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virusWilson Mok
Department of Radiation Oncology, Edwin L Steele Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 67:10664-8. 2007..Thus, these findings introduce a new approach to improve the delivery and efficacy of oncolytic viral vectors: modulation of tumor glycosaminoglycans to enhance convection... - Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse modelLei Xu
Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 65:5711-9. 2005.... - Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrowDan G Duda
Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
J Clin Invest 115:596-8. 2005.... - Differential transplantability of tumor-associated stromal cellsDan G Duda
E. L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 64:5920-4. 2004..These studies of tumor tissue transplantation provide a platform for exploring the role of epithelial-stromal interactions in studies of tumor heterogeneity and drug resistance... - Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancersDan G Duda
Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Oncol 25:4033-42. 2007..Finally, we offer a perspective on future research directions aimed at making this complex therapeutic approach successful in the clinic... - A 2-D/3-D model-based method to quantify the complexity of microvasculature imaged by in vivo multiphoton microscopyJames A Tyrrell
Department of Electrical, Computer and Systems Engineering, Rensselaer Polytechnic Institute, Troy, NY 12180-3590, USA
Microvasc Res 70:165-78. 2005..The resulting measures are expressed in units of information (bits). Synthetic and real-data examples are provided to illustrate the proposed measures... - Measurement of macromolecular diffusion coefficients in human tumorsEdward B Brown
Edwin L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Boston, MA 02114, USA
Microvasc Res 67:231-6. 2004..These measurements should help in modeling the transport of novel large MW therapeutics, and hence in estimating their distribution and efficacy in tumors... - The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesisIgor Garkavtsev
Edwin L Steele Laboratory for Tumour Biology, Department of Radiation Oncology Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Nature 428:328-32. 2004..These results indicate that ING4 has an important role in brain tumour pathogenesis... - Influence of the site of human gallbladder xenograft (Mz-ChA-1) on angiogenesis at the distant siteTakeshi Gohongi
Department of Surgery, Institute of Clinical Medicine, University of Tsukuba, Tsukuba shi 305 8575, Japan
Oncol Rep 11:803-7. 2004..The results of the present study together with our previous study imply that the primary tumor microenvironment is conducive to the angiogenesis at a distant site by the production of the endogenous angiogenesis inhibitor TGFbeta1... - Tumor microenvironment abnormalities: causes, consequences, and strategies to normalizeDai Fukumura
Department of Radiation Oncology, Edwin L Steele Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Cell Biochem 101:937-49. 2007..Combined anti-angiogenic and conventional therapies have shown promise in the clinic...
Research Grants
- Conference on Angiogenesis in Cancer and Other DiseasesRakesh Jain; Fiscal Year: 2002..The meeting's synthesis of available information will be particularly thought-provoking for students and post- doctoral fellows. ..
- Probing Tumor Microenvironment Using NanotechnologyRakesh K Jain; Fiscal Year: 2010..We also have the resources and the clinical collaborators in place to readily take our scientific findings to clinical trials (Nature Medicine, 2004, Cancer Cell, 2007). ..
- Role of BMDCs in Solid Tumor Growth and RelapseRakesh K Jain; Fiscal Year: 2010..Furthermore, our results will offer strategies for the inhibition of tumor relapse after radiotherapy by targeting molecular pathways that are critical for both angiogenesis and myeloid BMDC recruitment. ..
- Integrative Biology of Tumor MetastasisRakesh Jain; Fiscal Year: 2009..Finally, we have the resources and the clinical collaborators in place to initiate a clinical trial based on our findings, as attested by our ongoing trial using a VEGF-specific antibody. ..
- Probing Tumor Microenvironment Using NanotechnologyRakesh Jain; Fiscal Year: 2009..We also have the resources and the clinical collaborators in place to readily take our scientific findings to clinical trials (Nature Medicine, 2004, Cancer Cell, 2007). ..
- Role of BMDCs in Solid Tumor Growth and RelapseRakesh Jain; Fiscal Year: 2009..Furthermore, our results will offer strategies for the inhibition of tumor relapse after radiotherapy by targeting molecular pathways that are critical for both angiogenesis and myeloid BMDC recruitment. ..
- Training Program in Pathophysiology of Solid TumorsRakesh Jain; Fiscal Year: 2007..abstract_text> ..
- Role of BMDCs in Solid Tumor Growth and RelapseRakesh Jain; Fiscal Year: 2007..Furthermore, our results will offer strategies for the inhibition of tumor relapse after radiotherapy by targeting molecular pathways that are critical for both angiogenesis and myeloid BMDC recruitment. ..
- Anti-Angiogenesis/Drugs in Tumors--Bench /Bedside & BackRakesh Jain; Fiscal Year: 2005..Attendance at this conference will provide an excellent opportunity for young investigators working on cancer to educate and familiarize themselves with the field of angiogenesis and the complexities of the system. ..
- Probing Tumor Microenvironment Using NanotechnologyRakesh Jain; Fiscal Year: 2009..We also have the resources and the clinical collaborators in place to readily take our scientific findings to clinical trials (Nature Medicine, 2004, Cancer Cell, 2007). ..